


PHARMACEUTICAL 2017

Lexaria Bioscience Corp. Rank 254 of 292







PHARMACEUTICAL 2017

Lexaria Bioscience Corp. Rank 254 of 292



The relative strengths and weaknesses of Lexaria Bioscience Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Lexaria Bioscience Corp. is the variable Other Expenses, reducing the Economic Capital Ratio by 225% points.

The company's Economic Capital Ratio, given in the ranking table, is -215%, being 218% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	434
Liabilities, Non-Current	0
Other Assets	54
Other Compr. Net Income	0
Other Expenses	1,297
Other Liabilities	45
Other Net Income	0
Other Revenues	41
Property and Equipment	2.5
Research and Development	9.0
Selling, General and Administrative Expense	12

Output Variable	Value in 1000 USD
Assets	567
Liabilities	479
Expenses	1,318
Revenues	41
Stockholders Equity	88
Net Income	-1,277
Comprehensive Net Income	-1,277
Economic Capital Ratio	-215%

